statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
BOLT stock results show that Bolt Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth...

BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q4 2023

BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones BDC-3042 Phase 1 study successfully cleared safety assessments in the first...

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

REDWOOD CITY, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer...

Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.

Bolt Biotherapeutics Inc

Volume	13,475.00
52-Wk High	$2.03
52-Wk Low	$0.84

BOLT Bolt Biotherapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals